利福喷叮治疗肺结核合并乙肝28例的临床分析

目的 :探讨利福喷叮治疗肺结核合并乙肝的临床表现。方法 :对 2 8例肺结核合并乙肝病毒携带者用含利福喷叮方案治疗的结果及肝毒副作用进行分析 ,并以利福平为对照。结果 :治疗组和对照组二个月痰菌转阴率分别为 78.5 %和 85 .1% ,X线表现病灶总吸收率分别为 89.3%和 72 .1% ,治疗组肝损害发生率小于利福平组。结论 :利福喷叮是一种新的、有效的、安全的抗结核药物 ,疗效与利福平相当 ,对乙肝病毒携带者肝损害比利福平小 ,值得临床推广作用。

The Clinical Observed of Rifapentin Used to Cure Pulmonary Tuberculosis with Positive HBVm

Objective: To explore the clinical manifestations of rifapentin used to cure pulmonary tuberculosis with positive HBVM. Method: The incidence of liver injury of 28 cases treated with rifapentin was observed, while cases in the control group were treated with rifampin. Results: The sputum negative conversion rates in the 2nd month in treatments and contnol group were 78.9% and 85.1% respectively; the resolution of pulmonary lesions in the treatment and control groups accounted for 89.3% and 72.1% respectively; the drug adverse reaction rates were much lower than rifampine. Conclusion: Rifapentin is a new effective and safe anti-tuberculosis drug and its efficacy is equivalent to rifampine. The liver injury in HBVM positive group is less than in rafampine group, so it is worth using in clincal practice.